FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979470428> ?p ?o ?g. }

• W2979470428 abstract "Abstract Abstract 3382 Poster Board III-270 Recently, unrelated cord blood transplant (UCBT) has been widely applied to those who lack available related or unrelated donors. However, some results in those reports were conflicting, especially for transplantation-related mortality (TRM). The US study demonstrated a poor outcome for TRM in CBT recipients compared with human leukocyte antigen (HLA)–matched bone marrow transplant (BMT) recipients (NEJM. 2004; 351:2265). On the other hand, Takahashi et al showed excellent outcome (TRM 9% and disease free survival, DFS 70%) in CBT (Blood. 2007; 109:1322). Since there has been not much data available regarding this issue, we retrospectively extracted to adult patients with acute myeloid leukemia (AML) / myelodysplastic syndrome (MDS) and analyzed retrospectively the results of 245 recipients who underwent allogeneic stem cell transplantation (allo-SCT). We reviewed medical records of 290 patients with AML/MDS who had received allo-SCT from an unrelated donor between June 2000 and March 2009 at our institute, Tokyo, Japan. Since patients who had previous hematopoietic stem cell transplantations, active serious infection and performance status > 2, were excluded, 45 were subjected to the following analysis. Finally, the study includes 245 recipients of UCB (n = 140), UBM (n = 63), and related mobilized peripheral blood (RPB, n = 42) for de novo AML (n = 132), MDS overt AML (n = 79), refractory anemia (RA, n = 15), and refractory anemia with excess of blasts (RAEB, n = 19). Patient s median age for UCB, UBM, and RPB recipients were 59 (17 - 72), 55 (23 – 70), and 55 (22 – 67), respectively. UCB recipients had more serologically HLA-mismatched grafts (97% vs. 38% vs. 22%, P < .01), were conditioned more frequently with melphalan (75% vs. 27% vs. 20%, P < .01) and with total body irradiation (86% vs. 80% vs. 12%, P < .01 and used more tacrolimus (78% vs. 81% vs. 15%, P < .01) and less methotrexate (0% vs. 98% vs. 85%, P < .01) for graft-versus-host disease (GVHD) prophylaxis. Disease status consisted of standard (CR1 or CR2 of AML and RA, n = 62) and advanced groups(other status, n = 183). UCB recipients had significantly advanced status relative to UBM and RPB recipients (84% vs. 57% vs. 69%, P < .01) at the time of transplantation. Other characteristics such as sex, diagnosis, and body weight were balanced among three groups. Median follow-up time of survivors was 787 days (119 – 2314), 1050 days (244 – 3059), and 1287 days (141 – 3004) for UCB, UBM, and RPB recipients, respectively. The incidence of grade II–IV acute GVHD among evaluable UCB recipients was lower than those of UBM and RPB recipients (32% vs. 54% vs. 59%, P < .01). Similarly, the incidences of chronic GVHD for evaluable UCB, UBM, and RPB recipients were 36%, 69%, and 66%, respectively (P < .01). The estimated overall survival (OS) and DFS rates at 5 years post-transplantation were 36% (95% confidence interval Åm95%CIÅn; 25 - 47%) and 35% (95%CI; 26 - 44%) for UCB, 55% (95%CI; 40 - 69%) and 51% (95%CI; 37 - 64%) for UBM, and 39% (95%CI; 22 - 55%) and 25% (95%CI; 8 - 41%) for RPB (OS, P < .01 and DFS, P < .01). In the standard group, OS and DFS rates were not significantly different in the three groups (OS, UCB 63% vs. UBM 70% vs. RPB 49%, P = .39 and DFS, UCB 63% vs. UBM 70% vs. RPB 39%, P = .10). Similarly, in the advanced group, there were not significantly difference in the three groups (OS, UCB 30% vs. UBM 41% vs. RPB 35%, P = .23 and DFS, UCB 29% vs. UBM 38% vs. RPB 24%, P = .27). Compared with UBM and RPB recipients, UCB recipients had delayed hematopoietic recovery at 60 day (UCB 85% vs. UBM 97% vs. RPB 100%, Hazard ratio ÅmHRÅn= 0.49; 95%CI: 0.40 0.59; P < .01). Five-year estimated TRM and relapse rate (RR) were not significantly different in the three groups (TRM, UCB 34% vs. UBM 29% vs. RPB 50%, P = .39 and RR, UCB 30% vs. UBM 20% vs. RPB 28%, P = .28). < Conclusion> In this analysis, there was no apparent difference in the risks of TRM and RR between the UCB and UBM/RPB recipient groups. OS and DFS in both groups were also comparable among standard and advanced groups. Finally, our clinical results suggest that UCBT could be as safe and effective a stem-cell source as UBMT or RPB transplant for adult AML/MDS patient. Disclosures: No relevant conflicts of interest to declare." @default.
• W2979470428 created "2019-10-18" @default.
• W2979470428 creator A5006087511 @default.
• W2979470428 creator A5009982513 @default.
• W2979470428 creator A5010422580 @default.
• W2979470428 creator A5010644978 @default.
• W2979470428 creator A5028679667 @default.
• W2979470428 creator A5040021761 @default.
• W2979470428 creator A5054317516 @default.
• W2979470428 creator A5059414275 @default.
• W2979470428 creator A5064684895 @default.
• W2979470428 creator A5065324153 @default.
• W2979470428 creator A5074318520 @default.
• W2979470428 creator A5084336392 @default.
• W2979470428 date "2009-11-20" @default.
• W2979470428 modified "2023-09-29" @default.
• W2979470428 title "Comparative Single Institute Analysis of Cord Blood Transplantation From Unrelated Donors with Unrelated Bone Marrow or Related Peripheral Blood Stem-Cell Transplants in Adult Patients with Acute Myeloid Leukemia / Myelodysplastic Syndrome." @default.
• W2979470428 doi "https://doi.org/10.1182/blood.v114.22.3382.3382" @default.
• W2979470428 hasPublicationYear "2009" @default.
• W2979470428 type Work @default.
• W2979470428 sameAs 2979470428 @default.
• W2979470428 citedByCount "0" @default.
• W2979470428 crossrefType "journal-article" @default.
• W2979470428 hasAuthorship W2979470428A5006087511 @default.
• W2979470428 hasAuthorship W2979470428A5009982513 @default.
• W2979470428 hasAuthorship W2979470428A5010422580 @default.
• W2979470428 hasAuthorship W2979470428A5010644978 @default.
• W2979470428 hasAuthorship W2979470428A5028679667 @default.
• W2979470428 hasAuthorship W2979470428A5040021761 @default.
• W2979470428 hasAuthorship W2979470428A5054317516 @default.
• W2979470428 hasAuthorship W2979470428A5059414275 @default.
• W2979470428 hasAuthorship W2979470428A5064684895 @default.
• W2979470428 hasAuthorship W2979470428A5065324153 @default.
• W2979470428 hasAuthorship W2979470428A5074318520 @default.
• W2979470428 hasAuthorship W2979470428A5084336392 @default.
• W2979470428 hasConcept C126322002 @default.
• W2979470428 hasConcept C141071460 @default.
• W2979470428 hasConcept C203014093 @default.
• W2979470428 hasConcept C2777408962 @default.
• W2979470428 hasConcept C2778461978 @default.
• W2979470428 hasConcept C2778729363 @default.
• W2979470428 hasConcept C2779972918 @default.
• W2979470428 hasConcept C2780007613 @default.
• W2979470428 hasConcept C2780817109 @default.
• W2979470428 hasConcept C2780914630 @default.
• W2979470428 hasConcept C28328180 @default.
• W2979470428 hasConcept C2911091166 @default.
• W2979470428 hasConcept C54355233 @default.
• W2979470428 hasConcept C71924100 @default.
• W2979470428 hasConcept C86803240 @default.
• W2979470428 hasConcept C90924648 @default.
• W2979470428 hasConceptScore W2979470428C126322002 @default.
• W2979470428 hasConceptScore W2979470428C141071460 @default.
• W2979470428 hasConceptScore W2979470428C203014093 @default.
• W2979470428 hasConceptScore W2979470428C2777408962 @default.
• W2979470428 hasConceptScore W2979470428C2778461978 @default.
• W2979470428 hasConceptScore W2979470428C2778729363 @default.
• W2979470428 hasConceptScore W2979470428C2779972918 @default.
• W2979470428 hasConceptScore W2979470428C2780007613 @default.
• W2979470428 hasConceptScore W2979470428C2780817109 @default.
• W2979470428 hasConceptScore W2979470428C2780914630 @default.
• W2979470428 hasConceptScore W2979470428C28328180 @default.
• W2979470428 hasConceptScore W2979470428C2911091166 @default.
• W2979470428 hasConceptScore W2979470428C54355233 @default.
• W2979470428 hasConceptScore W2979470428C71924100 @default.
• W2979470428 hasConceptScore W2979470428C86803240 @default.
• W2979470428 hasConceptScore W2979470428C90924648 @default.
• W2979470428 hasLocation W29794704281 @default.
• W2979470428 hasOpenAccess W2979470428 @default.
• W2979470428 hasPrimaryLocation W29794704281 @default.
• W2979470428 hasRelatedWork W1979402464 @default.
• W2979470428 hasRelatedWork W2034333555 @default.
• W2979470428 hasRelatedWork W2075693165 @default.
• W2979470428 hasRelatedWork W2413153193 @default.
• W2979470428 hasRelatedWork W2413617597 @default.
• W2979470428 hasRelatedWork W2530340122 @default.
• W2979470428 hasRelatedWork W2547926736 @default.
• W2979470428 hasRelatedWork W2565028120 @default.
• W2979470428 hasRelatedWork W2572644617 @default.
• W2979470428 hasRelatedWork W2577342044 @default.
• W2979470428 hasRelatedWork W2580006679 @default.
• W2979470428 hasRelatedWork W2585642693 @default.
• W2979470428 hasRelatedWork W2587369420 @default.
• W2979470428 hasRelatedWork W2587905680 @default.
• W2979470428 hasRelatedWork W2590834799 @default.
• W2979470428 hasRelatedWork W2641696820 @default.
• W2979470428 hasRelatedWork W2768908225 @default.
• W2979470428 hasRelatedWork W2979612918 @default.
• W2979470428 hasRelatedWork W2980212997 @default.
• W2979470428 hasRelatedWork W2980441334 @default.
• W2979470428 isParatext "false" @default.
• W2979470428 isRetracted "false" @default.
• W2979470428 magId "2979470428" @default.
• W2979470428 workType "article" @default.